These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 23305079

  • 1. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A, Wassermann J, Warszawski-Baumann A, Baumann R, Machtens S, Karstens JH, Christiansen H, Merseburger A, Kuczyk MA, von Klot C.
    BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
    [Abstract] [Full Text] [Related]

  • 2. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M, Studer G, Le L, McLean M, Yeung I, Pond G, Crook JM.
    Brachytherapy; 2007 May; 6(3):173-9. PubMed ID: 17681239
    [Abstract] [Full Text] [Related]

  • 3. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN, Stock RG.
    Brachytherapy; 2003 May; 2(1):32-9. PubMed ID: 15062161
    [Abstract] [Full Text] [Related]

  • 4. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Keller B, Danjoux C, Szumacher E, Thomas G.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):811-7. PubMed ID: 19836166
    [Abstract] [Full Text] [Related]

  • 5. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T, Taussky D, Donath D, Le HP, Larouche RX, Béliveau-Nadeau D, Hervieux Y, Delouya G.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e377-83. PubMed ID: 21514068
    [Abstract] [Full Text] [Related]

  • 6. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J, Stock RG, Stone NN, Iannuzzi C, DeWyngaert JK.
    Radiat Oncol Investig; 1998 Nov 15; 6(3):135-41. PubMed ID: 9652912
    [Abstract] [Full Text] [Related]

  • 7. Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
    Teishima J, Iwamoto H, Miyamoto K, Shoji K, Masumoto H, Inoue S, Kobayashi K, Kajiwara M, Matsubara A.
    Int J Urol; 2012 Dec 15; 19(12):1083-9. PubMed ID: 22852805
    [Abstract] [Full Text] [Related]

  • 8. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M, Miller S, Pickles T, Halperin R, Kwan W, Lapointe V, McKenzie M, Spadinger I, Pai H, Chan EK, Morris WJ.
    Int J Radiat Oncol Biol Phys; 2014 Nov 01; 90(3):570-8. PubMed ID: 25151536
    [Abstract] [Full Text] [Related]

  • 9. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S, Cesaretti J, Stone NN, Stock RG.
    BJU Int; 2006 Nov 01; 98(5):979-81. PubMed ID: 17034599
    [Abstract] [Full Text] [Related]

  • 10. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
    Wust P, von Borczyskowski DW, Henkel T, Rosner C, Graf R, Tilly W, Budach V, Felix R, Kahmann F.
    Radiother Oncol; 2004 Oct 01; 73(1):39-48. PubMed ID: 15465144
    [Abstract] [Full Text] [Related]

  • 11. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA, Merrick GS, Butler WM, Wallner KE, Kurko B, Anderson RL, Murray BC, Galbreath RW.
    Int J Radiat Oncol Biol Phys; 2005 Jul 15; 62(4):981-7. PubMed ID: 15989998
    [Abstract] [Full Text] [Related]

  • 12. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M, Miller S, Moravan V, Pickles T, McKenzie M, Pai H, Liu M, Kwan W, Agranovich A, Spadinger I, Lapointe V, Halperin R, Morris WJ.
    Int J Radiat Oncol Biol Phys; 2009 Mar 15; 73(4):1023-32. PubMed ID: 19111402
    [Abstract] [Full Text] [Related]

  • 13. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds.
    Bottomley D, Ash D, Al-Qaisieh B, Carey B, Joseph J, St Clair S, Gould K.
    Radiother Oncol; 2007 Jan 15; 82(1):46-9. PubMed ID: 17161481
    [Abstract] [Full Text] [Related]

  • 14. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):e795-801. PubMed ID: 22330999
    [Abstract] [Full Text] [Related]

  • 15. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity.
    Merrick GS, Butler WM, Wallner K, Galbreath RW, Anderson RL, Kurko BS, Lief JH.
    Urology; 2002 Jul 01; 60(1):104-8. PubMed ID: 12100933
    [Abstract] [Full Text] [Related]

  • 16. Brachytherapy-related dysuria.
    Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Lief JH.
    BJU Int; 2005 Mar 01; 95(4):597-602. PubMed ID: 15705087
    [Abstract] [Full Text] [Related]

  • 17. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
    Dallas NL, Malone PR, Jones A, Doggart AJ, McConway KJ, Rogers PB.
    BJU Int; 2012 Aug 01; 110(3):383-90. PubMed ID: 22332791
    [Abstract] [Full Text] [Related]

  • 18. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 19. Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants.
    Smith RP, Jones HA, Beriwal S, Gokhale A, Benoit R.
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):745-50. PubMed ID: 20888139
    [Abstract] [Full Text] [Related]

  • 20. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
    Zebentout O, Apardian R, Beaulieu L, Harel F, Martin AG, Vigneault E.
    Cancer Radiother; 2010 Jun 01; 14(3):183-8. PubMed ID: 20418145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.